This is a clinical trial to compare a medication called eltrombopag to standard treatments (steroids, IVIG, or anti-D globulin) for children with newly diagnosed ITP. Eltrombopag is a medication that tells the bone marrow to make more platelets and, when tolerated and effective, can be continued until the ITP resolves or therapy is no longer needed. Eltrombopag is approved for children with chronic ITP so its safety in children has already been shown.
Eligibility Criteria
Ages eligible for study: 1-18 years
Platelets <30 x 10^9/L at screening
Requires pharmacologic treatment from the perspective of the treating clinician